Orthopedics giant Zimmer (NYSE:ZMH) is preparing to market a private-label version of MiMedx’s (NSDQ:MDXG) allograft products under the terms of a new agreement.
MiMedx agreed to provide Zimmer with dehydrated human amnion/chorion membrane allograft products under a non-exclusive private label basis, according to a press release.
Zimmer acquired rights to sell the products under its own label throughout the U.S. for a range of applications, including reconstructive, sports medicine, trauma, extremities and spinal uses.
"This agreement will facilitate a sizable expansion of the physicians and patients that will now have access to our dHACM allografts," MiMedx chairman & CEO Parker Petit said in prepared remarks. "The breadth of the applications included in the agreement and the large base of physicians, hospitals and other medical facilities served by Zimmer will enhance the presence of our allografts in the musculoskeletal sector of the market."
